Summary of medicine characteristics - Evant
-
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
EVANT suspension and solvent for oral spray for chickens
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (0.007 ml) of undiluted vaccine contains:
EVANT:
Active substances:
Eimeria acervulina, strain 003.....................................332 – 450*
Eimeria maxima, strain 013.........................................196 – 265*
Eimeria mitis, strain 006..............................................293 – 397*
Eimeria praecox, strain 007.........................................293 – 397*
Eimeria tenella, strain 004...........................................276 – 374* * Number of sporulated oocysts derived from precocious attenuated lines of coccidia, according to in vitro procedures of the manufacturer at the time of blending.
Adjuvant and excipients:
| Solvent | HIPRAMUNE T | HIPRACELL |
| Adjuvant | Montanide IMS | Light mineral oil |
| Excipients | Brilliant Blue (E133) | |
| Red AC (E129) | ||
| Vanillin | ||
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension and solvent for oral spray. Suspension: White turbid suspension. Solvent: Dark brownish solution.
4. CLINICAL PARTICULARS4.1 Target species
Chickens.
-
4.2 Indications for use, specifying the target species
For the active immunisation of chicks from 1 day of age to reduce intestinal lesions and oocysts output associated with coccidiosis caused by Eimeria acervulina, Eimeria maxima, Eimeria mitis, Eimeria praecox and Eimeria tenella and to reduce clinical signs (diarrhoea) associated with Eimeria acervulina , Eimeria maxima and Eimeria tenella.
Onset of immunity: 14 days post-vaccination.
Duration of immunity: 63 days post-vaccination in an environment that permits oocysts recycling.
4.3 Contraindications
None.
-
4.4 Special warnings for each target species
The vaccine will not protect species other than chickens against coccidiosis and is only effective against the Eimeria species indicated. This product is intended for the vaccination of short-lived chickens only. No data is available on protection of longer-lived birds such as future layers/breeders. Vaccinate healthy animals only.
-
4.5 Special precautions for use
Special precautions for use in animals
Chickens must be strictly floor-reared in the first 3 weeks after vaccination.
In order to reduce field infections, it is recommended that all litter should be removed and facilities and related equipment in contact with vaccinated chickens should be cleaned between production cycles.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash and disinfect hands and equipment after use.
-
4.6 Adverse reactions (frequency and seriousness)
None.
-
4.7 Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during lay. Do not use in birds in lay or in breeding birds, or within 4 weeks before the start of the laying period.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
No anticoccidial substances or other agents having anticoccidial activity via feed or water should be used for at least 3 weeks following the vaccination of chickens with this product otherwise the correct replication of the vaccine oocysts, and consequently the development of a solid immunity, could be hindered. Additionally, the duration of immunity depends on an environment that permits recycling of oocysts, therefore a decision to use any anticoccidial substances in the period after 3 weeks postvaccination should be made taking into account the potential negative impact on the duration of immunity of this product.
-
4.9 Amounts to be administered and administration route
Oral use.
The method of administration is by coarse spray.
Vaccination schedule:
One dose of vaccine (0.007 ml) from 1 day of age.
Administration:
The method of administration is by coarse spray by using a suitable device (volume delivered:
28 ml/100 chicks, droplet size: 200 – 250 ^m and working pressure: 1.5 to 3 bars).
Before starting to prepare the spray solution, ensure there is a clean container with sufficient capacity for preparing the diluted vaccine suspension available. Dilute the vaccine with the relevant volumes of the solvent (HIPRAMUNE T or HIPRACELL) and water, as shown in the following table:
| Doses | Water | Vaccine | Solvent | Total |
| 1,000 | 223 ml | 7 ml | 50 ml | 280 ml |
| 5,000 | 1,115 ml | 35 ml | 250 ml | 1,400 ml |
| 10,000 | 2,230 ml | 70 ml | 500 ml | 2,800 ml |
Shake the solvent (HIPRAMUNE T or HIPRACELL) vial. Dilute the content of the vial with clean, room temperature water into an appropriate container.
Shake the vaccine (EVANT) vial and dilute the contents of it into the solvent and water solution. A purplish suspension is obtained after dilution.
Fill the reservoir of the spraying device with all the vaccine suspension prepared.
Maintain the diluted vaccine suspension in continuous homogenisation by using a magnetic stirrer while the vaccine is being administered via coarse spray to the chicks.
To improve the uniformity of the vaccination, maintain the chicks inside the transportation box for at least 1 hour in order to let them ingest all the vaccine droplets.
After this time, place the chicks carefully into the litter and continue with regular management practices.
The device should be cleaned after each use. See the manufacturer’s instructions to ensure proper disinfection and maintenance of the device.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
After the administration of a severe overdose (10-fold), mild, transient, clinical signs of coccidiosis were commonly observed without any consequences on the final performance.
-
4.11 Withdrawal period(s)
Zero days.
-
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunological for Aves, live parasitic vaccines for domestic fowl. ATCvet code: QI01AN01.
To stimulate active immunity against coccidiosis caused by Eimeria acervulina , Eimeria maxima, Eimeria mitis, Eimeria praecox and Eimeria tenella.
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
EVANT (vaccine):
Potassium chloride
Disodium phosphate dodecahydrate
Potassium dihydrogen phosphate
Sodium chloride
Polysorbate 80
Purified water
HIPRAMUNE T (solvent):
Brilliant blue (E 133)
Red AC (E 129)
Vanillin
Montanide IMS
HIPRACELL (solvent):
Brilliant blue (E 133)
Red AC (E 129)
Vanillin
Light mineral oil
Polysorbate 80
Sorbitan mono-oleato
Potassium chloride
Disodium phosphate dodecahydrate
Potassium dihydrogen phosphate
Sodium chloride
Water for injections
6.2 Major incompatibilities
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.
6.3 Shelf life
EVANT:
Shelf life of the veterinary medicinal product as packaged for sale: 10 months.
Shelf life after dilution according to directions: 10 hours.
HIPRAMUNE T (solvent):
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
HIPRACELL (solvent):
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
6.4. Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
-
6.5 Nature and composition of immediate packaging
EVANT:
Type I colourless glass vials containing 7 ml, 35 ml or 70 ml of suspension (1,000, 5,000 and 10,000 doses) closed with type I polymeric elastomer closures and aluminium caps.
HIPRAMUNE T and HIPRACELL (solvents):
Polypropylene vials containing 50 ml, 250 ml or 500 ml of solvent closed with type I polymeric elastomer closures and aluminium caps.
Pack sizes:
Cardboard box with one vial of EVANT containing 7 ml (1,000 doses) and one vial of
HIPRAMUNE T containing 50 ml.
Cardboard box with one vial of EVANT containing 35 ml (5,000 doses) and one vial of
HIPRAMUNE T containing 250 ml.
Cardboard box with one vial of EVANT containing 70 ml (10,000 doses) and one vial of
HIPRAMUNE T containing 500 ml.
Cardboard box with one vial of EVANT containing 7 ml (1,000 doses) and one vial of HIPRACELL containing 50 ml.
Cardboard box with one vial of EVANT containing 35 ml (5,000 doses) and one vial of HIPRACELL containing 250 ml.
Cardboard box with one vial of EVANT containing 70 ml (10,000 doses) and one vial of
HIPRACELL containing 500 ml.
Not all pack sizes may be marketed.
-
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
7. MARKETING AUTHORISATION HOLDER
LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
Tel.: +34 972 430660
Fax: +34 972 430661
E-mail:
8. MARKETING AUTHORISATION NUMBER(S)
EU/2/18/233/001–006
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 05/02/2019.